A Multi-center, Randomized, Double-Blinded, Active Controlled, Non-Inferiority, Phase III Clinical Trial to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis
Latest Information Update: 21 Mar 2024
At a glance
- Drugs SP 5M 001 (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Shin Poong Pharmaceutical
Most Recent Events
- 21 Mar 2024 New trial record